Considerations on SARS-Cov-2 vaccines in patients with autoimmune blistering diseases

Eur J Dermatol. 2021 Jun 1;31(3):415-417. doi: 10.1684/ejd.2021.4043.
No abstract available

MeSH terms

  • Autoimmune Diseases / drug therapy
  • Autoimmune Diseases / immunology*
  • Blister / drug therapy
  • Blister / immunology*
  • COVID-19 / prevention & control*
  • COVID-19 Vaccines / administration & dosage*
  • Humans
  • Immunocompromised Host*
  • Immunosuppressive Agents / therapeutic use
  • SARS-CoV-2

Substances

  • COVID-19 Vaccines
  • Immunosuppressive Agents